Table 2.

Association between the presence of CD15 (0–3), CD15+MPO+ (0, 1), or CD15+MPO (0, 1) tumor-infiltrating cells, and clinical and immunological parameters in primary breast cancer.

Clinical and immunopathological featuresCD15 (0–3)CD15+ (PMN/MPO)+CD15+ (PMN/MPO)
Pearson’s chi-squared testa,b(N)Correlation CoefficientaP-valueCorrelation CoefficientaP-valueCorrelation CoefficientaP-value
ERαa(143)−0.1650.048c0.0040.962−0.1300.122
PRa(143)−0.0040.9580.1330.113−0.1100.188
Her2a(138)−0.0210.808−0.1280.1350.1340.115
TNBCa(138)0.2010.018c0.0030.9720.1770.037c
CD163 (M2 TAMs, MDSCs (0, 1))a(105)0.2260.020c0.1670.0890.0180.858
S100A9 (MDSCs (0–4))a(134)0.1520.079−0.0010.9940.1440.098
S100A9 (MDSCs (0–4))b(134)0.019c0.4660.028c
CD68 (TAMs (0, 1))a(107)0.1400.1500.0890.3620.0340.723
  • a Bivariate Pearson’s chi-squared.

  • b Pearson’s chi-squared.

  • c P < 0.05.